Swift Biotechnology LLC is developing cervical fluid screening tests to help detect ovarian and endometrial cancers during routine screening. The diagnostics could have improved sensitivity and accuracy over available blood tests, which could allow earlier detection of the cancers.

When caught early in stage I, ovarian cancer has a five-year survival rate higher than 95%. The problem is that only 10% are caught early, and the survival rate drops to about 25% when detected later. Early detection is limited because most patients do not have symptoms and screening is not routinely performed.